Kymera Therapeutics Announces Late-Breaking Oral Presentation of KT-621 Phase 1b Data at the American Academy of Dermatology (AAD) Annual Meeting
MWN-AI** Summary
Kymera Therapeutics, a clinical-stage biopharmaceutical company known for developing new oral small molecule degrader medicines for immunological diseases, has announced a significant milestone regarding its investigational treatment, KT-621. The company will present data from the KT-621 BroADen Phase 1b clinical trial during a late-breaking oral session at the American Academy of Dermatology (AAD) Annual Meeting, scheduled for March 27-31, 2026, in Denver, Colorado.
The presentation will focus on the clinical activity and safety of KT-621, a first-in-class oral degrader targeting STAT6, a key transcription factor associated with IL-4/IL-13 signaling—central to Type 2 inflammation prevalent in conditions like atopic dermatitis. The session will take place on Saturday, March 28, 2026, at 9:24 AM MT in the Bellco Theatre, with a recording of the presentation available on the company's website afterward.
Kymera's KT-621 is currently being evaluated in parallel Phase 2b trials for atopic dermatitis (BROADEN2) and asthma (BREADTH), with the potential to offer a novel treatment approach for the over 140 million individuals worldwide affected by Type 2 inflammatory diseases.
Kymera Therapeutics has gained recognition for its innovative work since its founding in 2016 and claims to be at the forefront of targeted protein degradation in developing effective therapies for immunological diseases. The company reiterates its focus on advancing its clinical and preclinical pipeline while addressing the evolving needs of patients. As Kymera navigates the complexities of drug development, investors and stakeholders are encouraged to consider the implications and potential of KT-621's progression through clinical trials.
MWN-AI** Analysis
Kymera Therapeutics, Inc. (NASDAQ: KYMR) recently made waves with its announcement of a late-breaking presentation at the upcoming American Academy of Dermatology (AAD) Annual Meeting regarding the KT-621 Phase 1b trial data. Investors should take note of the potential implications of this announcement, particularly in light of the rising interest and demand for innovative treatments in immunological diseases like atopic dermatitis.
KT-621 represents a pioneering approach as the first oral degrader targeting STAT6, a key player in Type 2 inflammation pathways. Given that over 140 million people worldwide are affected by such conditions, the market presents a substantial opportunity for Kymera. The success of KT-621 can not only validate Kymera's platform but also strengthen its position within the burgeoning field of targeted protein degradation (TPD).
As KYMR prepares for its presentation on March 28, 2026, investors should closely monitor reactions from clinicians and potential partnerships that may arise from this meeting. Positive data can amplify investor confidence, leading to a rise in stock value, while any shortcomings might raise red flags. Furthermore, the company’s simultaneous Phase 2b trials in atopic dermatitis and asthma could serve as additional value drivers moving forward.
Valuing Kymera should involve consideration of risk factors highlighted in their press release, specifically those associated with the uncertainties of clinical trials. The biotech sector is particularly volatile; thus, investors should manage their exposure accordingly.
In summary, while there are inherent risks, the upcoming AAD presentation could mark a pivotal point for Kymera. Investors might consider incremental positions leading up to the event, with the understanding that thorough scrutiny of KT-621’s clinical outcomes will ultimately guide future investment decisions.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
WATERTOWN, Mass., March 10, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that data from its KT-621 BroADen Phase 1b clinical trial in patients with atopic dermatitis will be presented in a late-breaking oral session at the American Academy of Dermatology (AAD) 2026 Annual Meeting. The meeting will be held March 27-31, 2026, in Denver, CO. Kymera will also host a booth (#3551) in the congress exhibit hall.
“We are honored to have our KT-621 BroADen Phase 1b data selected for a late-breaking oral presentation at AAD,” said Jared Gollob, MD, Chief Medical Officer, Kymera Therapeutics. “We look forward to engaging with the dermatology community at this important forum and sharing our work to develop novel oral medicines for patients living with chronic immuno-inflammatory diseases.”
AAD 2026 Late-Breaking Presentation Details
- Abstract Title: Clinical Activity and Safety of KT-621, an Oral STAT6 Degrader, in Moderate-to-Severe Atopic Dermatitis: Phase 1b Trial Results
- Session Title: Late-Breaking Research: Session 1
- Session Type: Oral Presentation
- Presentation Date/Time: Saturday, March 28, 2026, 9:24 AM MT
- Location: Bellco Theatre
A copy of the presentation will be available in the Resource Library section of Kymera's website after the session.
About KT-621
KT-621 is an investigational, first-in-class, once-daily oral degrader of STAT6, the specific transcription factor responsible for IL-4/IL-13 signaling and the central driver of Type 2 inflammation. KT-621 is currently being evaluated in parallel Phase 2b clinical trials in atopic dermatitis (BROADEN2) and asthma (BREADTH). By selectively targeting STAT6 for degradation, KT-621 has the potential to provide a novel oral approach for patients living with Type 2 inflammatory diseases, which affect more than 140 million people worldwide.
About Kymera Therapeutics
Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years. For more information about our science, pipeline and people, please visit www.kymeratx.com or follow us on X or LinkedIn.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements about our expectations regarding strategy, business plans and objectives on the development of our clinical and preclinical pipeline, including the therapeutic potential, clinical benefits and safety thereof. The words "may," "might," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "expect," "estimate," "seek," "predict," "future," "project," "potential," "continue," "target," “upcoming” and similar words or expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from any forward-looking statements contained in this press release, including, without limitation, risks associated with: that preclinical and clinical data, including the results from the Phase 1 trials of KT-621, are not predictive of, may be inconsistent with, or more favorable than, data generated from future or ongoing clinical trials of the same product candidate, uncertainties inherent in the initiation, timing and design of future clinical trials, the availability and timing of data from ongoing and future clinical trials and the results of such trials, the ability to successfully demonstrate the safety and efficacy of drug candidates, the unexpected emergence of adverse events or other undesirable side effects during preclinical and clinical development, and other factors. These risks and uncertainties are described in greater detail in the section entitled "Risk Factors" in the most recent Quarterly Report on Form 10-Q and in subsequent filings with the SEC. In addition, any forward-looking statements represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. We explicitly disclaim any obligation to update any forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.
Investor Contact:
Justine Koenigsberg
Vice President, Investor Relations
investors@kymeratx.com
857-285-5300
Media Contact:
Matthew Henson
Vice President, Corporate Communications
mhenson@kymeratx.com
857-285-5300
FAQ**
How does the late-breaking data from the KT-621 BroADen Phase trial contribute to the investment outlook for Kymera Therapeutics Inc. KYMR in the competitive field of immunological disease treatments?
What are the key expectations surrounding the efficacy and safety of KT-621, the oral STAT6 degrader, as presented by Kymera Therapeutics Inc. KYMR at the AAD 20Annual Meeting?
In light of Kymera Therapeutics Inc. KYMR's focus on targeted protein degradation, how might the results of the KT-621 BroADen trial affect its future pipeline and investor confidence?
Given the announcement and upcoming presentation by Kymera Therapeutics Inc. KYMR, what potential risks should investors consider related to its clinical trials and the development of oral small molecule degraders?
**MWN-AI FAQ is based on asking OpenAI questions about Kymera Therapeutics Inc. (NASDAQ: KYMR).
NASDAQ: KYMR
KYMR Trading
-3.9% G/L:
$82.97 Last:
199,131 Volume:
$83.51 Open:
